iBio Announces Proposed Public Offering of Pre-Funded Warrants and Accompanying Series G and H Warrants.

iBio, Inc. has announced a proposed public offering of pre-funded warrants and accompanying Series G and H warrants. The offering will be subject to market and other conditions, and there is no assurance as to whether or when the offering may be completed. The company intends to use the net proceeds from the offering for general corporate purposes.

SAN DIEGO, Aug. 18, 2025 — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, has announced a proposed public offering of pre-funded warrants and accompanying Series G and H warrants. The offering is expected to close on or about August 22, 2025, subject to satisfaction of customary closing conditions [2].

The public offering consists of two components: pre-funded warrants and accompanying Series G and H warrants. Pre-funded warrants will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Series G and Series H warrants will each be exercisable from their date of issuance and will have an exercise price equal to $0.70 per share of iBio’s common stock [2].

The combined public offering price of one pre-funded warrant and one Series G warrant to purchase one-half of a share of common stock, or a pre-funded warrant in lieu thereof, and one Series H warrant to purchase one-half of a share of iBio’s common stock, or a pre-funded warrant in lieu thereof, is $0.699 [2].

The estimated gross proceeds from the offering are expected to be approximately $50 million before deducting underwriting discounts and commissions and offering expenses [2]. iBio intends to use the net proceeds from the offering to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, through key development milestones, as well as to continue to progress its other preclinical pipeline assets, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes [2].

The offering is being made by iBio pursuant to a shelf registration statement on Form S-3 (File No. 333-280680), as amended [2]. Leerink Partners acted as the lead bookrunner for the offering, with LifeSci Capital and Oppenheimer & Co. acting as bookrunning managers, and Brookline Capital Markets, a division of Arcadia Securities, LLC, acting as a financial advisor to iBio [2].

References:
[1] https://www.ainvest.com/news/day-biopharmaceuticals-shares-rise-1-62-intraday-ibio-announced-public-offering-pre-funded-warrants-2508/
[2] https://www.globenewswire.com/news-release/2025/08/19/3135662/0/en/iBio-Announces-Pricing-of-50-Million-Public-Offering.html
[3] https://ir.ibioinc.com/news-events/press-releases/detail/243/ibio-announces-proposed-public-offering